Condition: Heterozygous Familial Hypercholesterolemia (HeFH) · Sponsor: Assistance Publique - Hôpitaux de Paris
This multicenter, non-randomized interventional study aims to assess coronary artery disease progression over 5 years in patients with genetically confirmed heterozygous familial hypercholesterolemia (HeFH), using coronary computed tomography angiography (CCTA). The primary endpoint is the visual evaluation of coronary stenosis using CAD-RADS v2.0, identifying changes between baseline (2018-2022) and study inclusion. The study will enroll 300 patients (100 protected, 200 non-protected) from La Pitié-Salpêtrière hospital and Saint Antoine Hospital (Paris). Participation lasts up to one week. Total study duration is 2 years, with extended follow-up through routine care data over 10 years.
This description comes directly from the study's public registry record.
Antonio GALLO, MD, PhD · 33(0)1 42 17 57 74 · antonio.gallo@aphp.fr
Franck BOCCARA, MD, PhD · 33(0)1 49 28 24 49 · franck.boccara@aphp.fr
Always discuss trial participation with your own doctor first.
| Plateau d'investigation clinique (PIC) IHU-ICAN | Paris, France | Not Yet Recruiting |
| APHP- Hospital Saint-Antoine | Paris, Île-de-France Region, France | Not Yet Recruiting |
| APHP-Sorbonne, Pitié Salpêtrière Hospital | Paris, Île-de-France Region, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07427472